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Role of transforming growth factor (TGF)-pl in experimental chronic
cyclosporine nephropathy. The pathogenesis of fibrosis in chronic cyclo-
sporine (CsA) nephropathy remains unknown. Since TGF-f31 plays a key
role in the fibrogenesis of a number of renal diseases, we studied a
salt-depleted rat model of chronic CsA nephropathy which shows similar-
ity to the structural and functional lesions described in patients. Pair fed
rats were treated with either CsA (15 mg/kg/day s.c.) or an equivalent dose
of olive oil and sacrificed at 7 and 28 days. Characteristic histologic
changes of proximal tubular injury, tubulointerstitial fibrosis and arteriol-
opathy developed in CsA-treated rats at day 28. They were accompanied
by physiologic changes of increased serum creatinine, decreased creatinine
clearance, increased enzymuria and decreased concentrating ability. CsA-
treated rats showed a progressive increase in mRNA expression of
TGF-1 and matrix proteins at days 7 and 28. Most of the changes were
in the tubulointerstitial and vascular compartments by immunofluores-
cence with a predominant involvement of the medulla as compared to
cortex. The mRNA expression of plasminogen activator inhibitor, a
protease inhibitor stimulated by TGF-pl, followed TGF-/31 and matrix
proteins, suggesting that the fibrosis of chronic CsA nephropathy likely
involves the dual action of TGF-p on matrix deposition and degradation.
The introduction of cyclosporine A (CsA) into clinical practice
has resulted in a major improvement in the short term outcomes
of solid organ transplantation [1] and the treatment of autoim-
mune diseases [2]. However, with increased use has come the
recognition that CsA has severe deleterious effects on renal
structure and function making chronic nephrotoxicity a major
limiting side effect [3]. Acute renal dysfunction due to CsA is
reversible since it involves renal hemodynamic dysfunction and is
not associated with any permanent histologic changes [4]. On the
other hand, chronic CsA nephrotoxicity may progress to an
irreversible renal lesion characterized by striped interstitial fibro-
sis, tubular atrophy and hyalinosis of the afferent arterioles [5, 6].
Chronic CsA nephrotoxicity has been described in kidneys of
recipients of renal and other organ allografts, as well as in patients
treated with CsA for autoimmune diseases [7—9]. In addition,
progression to end-stage renal disease with chronic CsA use is
well documented [10]. However, the exact mechanism underlying
the development of fibrosis in chronic CsA nephrotoxicity remains
poorly understood [11]. The observed striped interstitial fibrosis
does not improve consistently with discontinuation of the drug
and occurs even in patients treated with low doses of CsA [6].
Because the fibrotic lesion of chronic UsA nephrotoxicity has been
difficult to reproduce in animals, the lack of an animal model of
chronic CsA nephrotoxicity has hampered the study of its patho-
genesis. Using the observation that sodium depletion exacerbates
CsA nephrotoxicity, a reproducible animal model of chronic CsA
nephrotoxicity was recently established [12]. In this model, CsA
treatment in rats on low salt diet induced physiologic and histo-
logic features that resemble the human lesion described in
patients on long-term CsA therapy [13].
To date, no study has looked at the components of the fibrotic
lesion of chronic UsA nephrotoxicity in vivo and none has
attempted to correlate the renal fibrosis or the expression of ECM
components with any growth factor, Transforming growth fac-
tor-p (TGF-/3) has been implicated in the fibrosis of a number of
chronic diseases of the kidney and other organs [14, 15]. TGF-f3
directly stimulates the synthesis of individual ECM components
[16—18]. It also blocks ECM degradation by decreasing the
synthesis of proteases and stimulating protease inhibitors like
plasminogen activator inhibitor-i (PAl-i) [19]. In addition to its
effect on matrix accumulation, TGF-/3 also promotes immune
suppression [20, 21].
Since TGF-13 is a key fibrogenic cytokine, we hypothesized that
TGF-13 overexpression might he responsible for the fibrosis of
chronic CsA nephrotoxicity. To test this hypothesis, we utilized
this animal model with lesions similar to human chronic CsA
nephropathy. Our findings indicate that fibrosis is mostly ex-
pressed in the medulla, that all major components of the ECM are
elevated and that their expression correlates with an increased
expression of TGF-p and PAl-i. These results suggest that the
ECM accumulation observed with chronic CsA therapy likely
involves the dual action of TGF-p on ECM deposition and
degradation.
Methods
Experimental design
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Adult, male Sprague-Dawley rats (Charles River, Wilmington,
MA, USA), 225 to 250 g, were housed in individual cages in a
temperature and light controlled environment, and received a low
salt diet (0.05% sodium, Teklad, Premier, WI, USA), with water
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ad libitum. After one week on the low salt diet, weight matched
pairs of rats were randomly assigned to receive daily subcutaneous
injections of CsA 15 mg/kg (Sandimmune®, Sandoz Research
Institute, East Hanover, NJ, USA), or an identical volume of the
vehicle olive oil as a control. Control rats were fed the exact
amount of food consumed the day before by the CsA-treated rats.
Animals were divided into two groups of 16 CsA-treated and 16
control rats. Eight rats from each group were studied at days 7 and
28. Body weight was recorded daily. At the end of each treatment
period, 24-hour quantitative urine samples were collected in
metabolic cages (Nalge Co., Rochester, NY, USA) and systolic
blood pressure (BP) was measured by tail plethysmography
(Narco Bio-systems, Houston, TX, USA). The following day
animals were anesthetized with ketamine and a blood sample was
obtained. After opening the abdomen through a midline incision,
the abdominal aorta was cannulated retrogradely below the renal
arteries with an 18-gauge needle. With the aorta occluded by
ligation above the renal arteries and the renal veins opened by a
small incision for outflow, the kidneys were perfused with 20 ml of
cold heparinized saline. The kidneys were removed, the cortex
was carefully dissected from the medulla, and the tissues were
processed for evaluation by light microscopy, RNA analysis and
immunohistochemistry.
Functional studies
Urinary and plasma sodium were measured by flame photom-
eter (Instrumentation Laboratories, Lexington, MA, USA). Uri-
nary and plasma osmolality were measured by freezing point
depression (Osmette A, Precision Systems Inc., Natick, MA,
USA). Urinary and serum creatinine, urinary protein (Uprot),
urinary alanine aminopeptidase (AAP) and urinary N-acetyl
/3-D-glucosaminidase (NAG) were measured by a Cobas autoana-
lyzer (Roche Diagnostics, Div. Hoffman-La Roche Inc., Nutley,
NJ, USA). CsA blood levels were determined in whole blood by a
specific radioimmunoassay (Incstar Corp., Stillwater, MN, USA).
The creatinine clearance (Ce,.), fractional excretion of sodium
(FENa) and free water reabsorption (TcW) were calculated using
standard formulae.
Morphology
Renal tissue samples were fixed in 10% buffered formalin and
embedded in paraffin. Two to four micron thick sections were
stained with periodic acid-Schiff's reagent (PAS) and Trichrome.
Horizontal and sagittal sections were both performed. The histo-
logic findings were subdivided into three categories: proximal
tubular injury, interstitial inflammation and scarring, and arteriol-
opathy. Findings ascribed to tubular injury included cellular and
intercellular vacuolization, tubular collapse (unassociated with
interstitial fibrosis or tubular membrane thickening) and tubular
distention. Features of interstitial inflammation were mononu-
clear infiltrates, edema and vacuolization of interstitial cells. The
findings of scarring were matrix-rich expansion of the interstitium
with distortion of the tubules and thickening of the tubular
basement membranes. Renal arteriolopathy in chronic CsA-
induced nephrotoxicity was characterized by hyalinization and
destruction of the afferent arterioles. The hyalinosis consisted of
hyalin deposition within the tunica media of afferent arterioles
and terminal portion of interlobular arteries. A minimum of 20
fields at lOOx magnification were assessed and graded in each
Table I. Physiologic parameters in CsA and placebo (VH) treated rats
at 7 and 28 days
Day 7 Day 28
VH CsA VH CsA
Sr mg/dl
Cr
0.37 0.02
0.55 0.02
0.48 0.02
0.41 0.02"
0.37 0.03
0.59 0.05
1.04 0.12"
0.22 0.03"
ml/min/100 g
FENa % 0.06 0.01 0.04 0.01 0.02 0.01 0.05 0.01
Urine AAP 45 10 168 34 52 8 86 21
IU/gCr
Urine NAG 25 1 31 4 20 1 27 1
IU/gCr
UV 10.2 1.2 12.9 1.4 11.6 1.3 24.8 3.2"
ml/24 hr
U0sm 1,848 253 1,037 178" 1,344 168 662 110"
mOsm/kg
TcW 49±6 28±5" 34±2 23±6
ml/24 hr
Data are mean SEM of eight rats. Abbreviations are: VH, placebo; Sr,
serum creatinine; C, creatinine clearance; FENa, fractional excretion of
sodium; AAP, alanine aminopeptidase; NAG, N-acetyl J3-D-glucosamini-
dase; UV, urinary volume; Uom, urinary osmolality; TcW, free-water
reabsorption.
a P < 0.01 vs. VH
"P < 0.05 vs. VH
biopsy by an observer masked to treatment groups using a color
image analyzer (Olympus CIA-102, Olympus Inc., Tokyo, Japan).
The following semiquantitative score was used to asses the
extent of changes in each category. For tubular injury, the
following score was utilized: 0 no tubular injury; 0.5 = <5% of
tubules injured; 1 = 5 to 20% of tubules injured; 1.5 = 21 to 35%
of tubules injured; 2 = 36 to 50% of tubules injured; 2.5 = 51 to
65% of tubules injured and 3 = > 65% of tubules injured.
Tubulointerstitial fibrosis was estimated by counting the percent-
age of injured areas per field of cortex and medulla, and was
scored semiquantitatively using the following: 0 = normal inter-
stitium; 0.5 = < 5% of areas injured; I = 5 to 20% of areas
injured; 1.5 = 21 to 35% of areas injured; 2 = 36 to 50% of
areas injured; 2.5 = 51 to 65% of areas injured and 3 = > 65%
of areas injured. Hyalinosis of the afferent arterioles was
semiquantitatively determined by counting the percentage ofjuxtaglomerular afferent arterioles available for examination
with a minimum of 100 glomeruli per biopsy assessed: 0 = no
arterioles injured; 0.5 = < 15% of arterioles injured; 1 = 15 to
30% of arterioles injured; 1.5 = 31 to 45% of arterioles injured;
2 = 46 to 60% of arterioles injured; 2.5 = 61 to 75% of
arterioles injured and 3 = > 75% of arterioles injured.
RNA analysis
After separating the cortex from the medulla, the tissue was
finely minced with a razor blade on ice. Total RNA was prepared
by lysis in 4 M guanidine isothiocyanate containing 1% 2-mercap-
toethanol and 0.5% lauryl sarcosyl and ultracentrifugation of the
lysate on a cesium chloride cushion. After resuspending in
Tris-EDTA buffer, RNA concentrations were determined using
spectrophotometric readings at Absorbance260. Thirty micro-
grams of RNA were electrophoresed in each lane in 0.9% agarose
gels containing 2.2 M formaldehyde and 0.2 M Mops (pH 7.0) and
transferred to a nylon membrane (ICN Biomedicals, Inc., Costa
Mesa, CA, USA) overnight by capillary blotting. Nucleic acids
a.5-..
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Fig. 1. Histologic changes in experimental chronic CsA nephrotoxicily. Micrograph showing the renal cortex of a salt-depleted rat given CsA, 15 mg/kg/day
during four weeks. Striped tubulointerstitial fibrosis and tubular atrophy are extensive in this animal (A). There is also focal smooth muscle injury of
the glomerular afferent arteriole showing hypertrophied and granular eosinophilic transformation (B) (periodic acid-Schiff, magnification X200).
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were crosslinked by ultraviolet irradiation (Stratagene, La Jolla,
CA, USA). The membranes were prehybridized for two hours at
42°C with 50% formamide, 10% Denhardt's solution, 0.1% SDS,
5X standard saline citrate (SSC), and 200 j.tg/ml denatured
salmon sperm DNA. They were then hybridized at 42°C for 18
hours with cDNA probes labeled with 32P-dCTP by random
oligonucleotide priming (Boehringer Mannheim Corp., Indianap-
olis, IN, USA). The blots were washed in 2 >< SSC, 0.1% SDS at
room temperature for 15 minutes and in 0.1 x SSC, 0.1% SDS at
50°C for 15 minutes. Films were exposed at —70°C for different
time periods to ensure linearity of densitometric values and
exposure time. Autoradiographs were scanned on a laser densi-
tometer (Ultrascan XL; Pharmacia LKB Biotechnology, Inc.).
The density of bands for the glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA was used to control for differences
in the total amount of RNA loaded onto each gel line. For
quantitative purposes, the values were divided by the density of
bands for GAPDH in the same lane. The following probes were
used for Northern blot analysis.
A mouse TGF-/31 cDNA probe (plasmid MUI5) was kindly
provided by R. Deiynck [22]. A rat PAl-I cDNA probe [plasmid
pBluescript SK(—)] was obtained from T.D. Gelehrter [23].
Plasmid P16, which contains a human biglycan insert, was a gift of
L.W. Fisher [241. A rat decorin cDNA probe (plasmid pGEM4)
was provided generously by K.L. Dreher [25]. A rat procollagen
al cDNA (plasmid paiRl) was obtained from D. Rowe [261. A
rat GAPDH cDNA probe (plasmid pBluescript KS II) was a gift
from J.M. Blanchard [27].
Immunohistochemistiy
Immunofluorescence microscopy was performed on tissues
snap frozen in cold isopentane with a clyostat microtome (Miles
Scientific, Naperville, IL, USA) as previously described [28]. Four
micrometer cryostat sections were fixed in acetone and washed in
PBS, pH 7.4. The deposition of the following ECM components,
decorin, tenascin and fibronectin-cellular containing extra domain
A (fibronectin EDA+) was performed. The primary antibody for
decorin was a rabbit anti-human decorin antibody and was
provided by E. Ruoslahti (La Jolla, CA, USA) [29]. The other
primary antibodies used were rabbit anti-human tenascin (Life
Technologies, Gaithersburg, MD, USA) and mouse anti-human
fibronectin EDA+ (Sera-lab, Crowley Down, UK). The secondary
antibodies used were fluorescein isothiocyanate (FITC)-conju-
gated F(ab')2 donkey anti-rabbit IgG (Jackson Immunoresearch,
West Grove, PA, USA) and FITC-conjugated F(ab')2 rat anti-
mouse IgG (Jackson Immunoresearch). A minimum of 20 randomly
selected areas per sample were observed at X250 magnification.
The severity of staining for the glomerular, tubulointerstitial and
vascular compartments was evaluated by an observer blinded to
the treatment groups using the following semiquantitative scale:
0 = diffuse, very weak or absent staining, 1 = staining involving
less than 25%, 2 = staining involving 25% to 50%, 3 = staining
involving 50% to 75% and 4 = staining involving 75% to 100%.
Photographs were obtained at identical exposure and develop-
ment time intervals.
Statistical analysis
Results are presented as mean SEM. Multiple comparisons
were done by analysis of variance. Comparisons between CsA and
VH animals were done by two-tailed unpaired Student's t-test or
Table 2. Semiquantitative scoring by light microscopy of the extent of
changes observed in the chronic CsA lesion for proximal tubular injury,
tubulointerstitial fibrosis and arteriolopathy
Day 7 Day 28
VH CsA VH CsA
Proximal tubular injury 0.1 0.1 0.6 0.2 0.1 0.1 1.5 0.2°
Tubulointerstitial fibrosis 0 0 0 0 0.1 0.1 1.6 0.3°
Arteriolopathy 0 0 0 0 0.1 0.1 1.6 0.2°
Data are mean SEM of eight rats. VH is control.
P < 0.01 vs. VH
Mann-Whitney test, as appropriate. The level of statistical signif-
icance was chosen as P < 0.05.
Results
Physiologic studies
Although weight gain was progressive in the two treatment
groups, animals treated with CsA failed to gain as much weight as
those receiving vehicle (VH) with the difference achieving statis-
tical significance (P < 0.01) at day 28. CsA-induced hypertension
was not observed in this model; in fact, in CsA-treated rats, mean
systolic BP tended to be numerically lower than in VH-treated
rats, although the difference was not statistically significant. There
was a progressive increase in CsA whole blood level in CsA-
treated animals: 2930 250 ng/ml at day 7 and 5827 301 ng/ml
at day 28.
CsA induced a significant increase in serum creatinine (Sr)
only at day 28 (P < 0.01) (Table 1). On the other hand, the Cc1.
was already lower in the CsA-treated rats at day 7 (P < 0.05) and
was progressively lower at day 28 (P < 0.01) (Table 1). There was
no significant proteinuria in the CsA-treated rats or the placebo
animals.
The fractional excretion of sodium (FENa) was significantly
decreased compared to normal in CsA-treated and placebo
animals at all time points, reflecting the low sodium diet (Table 1).
CsA caused an increase in the urinary excretion of AAP at days 7
and 28 that was significant at day 7 (P < 0.01; Table 1). Urinary
NAG excretion was also higher at both time intervals, but did not
reach statistical significance (Table 1). Urinary concentrating
ability was clearly impaired as indicated by the progressive and
significant increase in urinary volume by day 28 (P < 0.01) and
decrease in U0sm by day 7 (P <0.05) and day 28 (P < 0.01) (Table
1). There was also a decrease in TcW at both time intervals,
although it was statistically significant only at day 7 (P < 0.05;
Table 1).
Histologic changes
CsA-treated rats had characteristic morphologic findings simi-
lar to the chronic human lesion, mostly evident at day 28. There
was a mononuclear cell infiltrate and an early tubular injury by day
7. However, the typical lesion of chronic CsA nephrotoxicity was
observed by day 28 (Fig. 1). Findings ascribed to tubular injury
consisted of cellular and intercellular vacuolization, tubular col-
lapse and tubular dilatation. Striped interstitial fibrosis was
present with progressive inflammatory cell infiltrates associated
with thickening of the tubular basement membranes (TBM) and
Bowman's capsule. There was focal disruption of the TBM in
some areas of interstitial infiltrate with loss of tubular definition.
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The vascular lesion was characterized by arteriolar hyalinosis
consisting of hyalin deposition within the tunica media of afferent
arterioles and the terminal portions of the interlobular arterics.
The extent of changes was graded (Table 2) using a 0 to 3 +
semiquantitative scale, with 3 + indicating extensive changes. In
this model, while no early histologic changes were observed by day
7, changes of chronic CsA nephrotoxicity manifested as proximal
tubular injury, tubulointerstitial fibrosis and arteriolopathy devel-
oped by 28 days (P < 0.01) when compared to VH-treated rat
kidneys.
Expression of TGF-131 and PAl-i mRNA
TGF-pl mRNA was progressively increased by day 7 (P <
0.00 1) and more so at day 28 (P < 0.001) in the CsA-treated rats
when compared to control VH rats (Figs. 2 and 3). The mRNA
expression of PAl-i, a protease inhibitor that blocks ECM
degradation by the plasmin protease system and is directly
stimulated by TGF-f3, is shown in Figures 2 and 4. PAl-i mRNA,
in parallel to TGF-f31 mRNA expression, was progressively
up-regulated in the CsA-treated rats at seven days (P < 0.001) and
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Fig. 2. Northern blotting of mRNA from cortex
and medulla in GsA and VH-ireated rat kidneys.
Total RNA was isolated from whole cortex and
medulla at days 7 and 28 from rats treated with
— 1 .3 CsA 15 mg/kg/day or VH control and was hybrid-
ized with eDNA probes to (A) TGF-j31, (B)
PAT-i, (C) biglycan, (D) decorin, (E) type I
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Fig. 3. uantitation of mRNA expression of TGF-/31 in Gs  and II-
treated rat kidneys relative to P . Total R  was isolated from whole
Cortex and edulla at days 7 and 28 and as hybridized ith a e
probe to TGF-1. Symbols are: (U) CsA 7 days; () H 7 days; () s
28 days, (D) VH 28 days. N = 8 for each group. **p < 0.001 compared to
H control.
Fig. 4. Quantitation of mRNA expression of PA 1-1 in GsA and VH-treated
rat kidneys relative to GAPDH. Total RNA was isolated from whole Cortex
and medulla at days 7 and 28 and was hybridized with a cDNA probe to
PAT-i. Symbols are: (U) CsA 7 days; () VH 7 days; () CsA28 days, ()
VH 28 days. N = 8 for each group. **p < 0.001 compared to VH control.
more so at 28 days (P < 0.001) as compared to control VH rats
(Fig. 4).
Extracellular matrix deposition in the kidney
Northern blot analysis. The proteoglycans biglycan and decorin
are components of the ECM. Their mRNA expression was
Fig. 5. Quantitation of mRNA expression of the proteoglycans, biglycan and
decorin, in ('sA and VH-treated rat kidneys relative to P . Total RNA
as isolated fro  hole cortex and edulla at days 7 and 28 and was
hybridized with a eDNA probe to (A) biglycan and (B) decorin. Symbols
are: (U) CsA 7 days; () VH 7 days; () CsA 28 days, () VH 28 days.N = 8 for each group. *D < 0.005 and ** < 0.001 compared to VU
control.
elevated in this model suggesting active matrix synthesis (Figs. 2
and 5). Biglycan mRNA expression closely followed TGF-131
mRNA expression and was progressively elevated at seven days
(P < 0.005 for cortex and < 0.001 for medulla) and at 28 days
(P < 0.001) when compared to control VH. The behavior of the
other proteoglycan, deeorin, was somewhat different. At day 7, it
was not statistically elevated when compared to VH control but
was definitely up-regulated by day 28 (P < 0.001). Collagen type
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early expression of fibronectin EDA+ at day 7 (P < 0.001) that
decreased by day 28 to control level.
The deposition of decorin followed its mRNA expression and
that of tenascin and fibronectin EDA+ (Figs. 7 and 8). Most of
the changes were observed at day 7 in the vessels (P < 0.001) and
tubulointerstitium (P < 0.001) with no elevated expression in the
glomeruli when compared to VH controls.
Differential expression in cortex and medulla
The differential expression in the cortex versus the medulla for
TGF-/31, PAt-I and the ECM proteins was examined by Northern
blots. As shown in Figure 9, the changes observed in mRNA
expression for TGF-/31, PAl-i, type I collagen and the proteogly-
cans, biglycan and decorin, although present in the cortex, was
more dramatic and significant (P < 0.001) in the medulla as
compared to the cortex at both days 7 and 28.
Discussion
Fig. 6. Quantitation of mRNA expression of type I collagen in CsA and
VH-treated rat kidneys relative to GAPDH. Total RNA was isolated from
whole Cortex and medulla at days 7 and 28 and was hybridized with a
cDNA probe to type I collagen, N = 8 for each group. Symbols are: (•)
CsA 7 days; () VH 7 days; () CsA 28 days, () VH 28 days. *P < 0.005
and ** < 0.001 Compared to VH control.
I is normally present in the interstitial compartment of the kidney
and is directly increased by TGF-13. In this model, the mRNA
expression of type I collagen followed TGF-131 and PAl-i mRNA
expression and was progressively up-regulated at day 7 (P <0.005
for cortex and < 0.001 for medulla) and day 28 (P < 0.001; Fig.
6).
Immunohistochemisity. Certain components of the ECM were
also examined by immunotluorescence in order to assess whether
the increased mRNA expression of matrix proteins was translated
into increased protein synthesis and deposition into matrix. This
allowed us to assess which compartments of the kidney (glomeruli,
vessels or tubulointerstitium) were most extensively involved in
matrix expansion. We examined the expression of tenascin, fi-
bronectin EDA+, and decorin. The amount of tenascin and
fibronectin EDA+ was elevated in the kidneys of CsA-treated rats
as compared to VH controls at both days 7 and 28 in all the kidney
compartments (Figs. 7 and 8).
The changes were most significant in the tubulointerstitium for
both tenascin (P < 0.005 at days 7 and 28) and fibronectin EDA+
(P < 0.005 at day 7 and < 0.01 at day 28; Fig. 8). The arteriolar
hyalinosis observed in this model correlated with a progressive
and significant increase in the expression of tenascin and fibronec-
tin EDA+ in the vascular compartment of the kidneys of CsA-
treated rats. While it was significant for fibronectin EDA+ at day
7 (P < 0.005) and day 28 (P < 0.005), the expression of tenascin
did not reach statistical significance until day 28 (P < 0.01) when
compared to VH controls (Fig. 7). Most of the changes reached
statistical significance in the tubulointerstitium and vascular com-
partments of the kidney, in accordance with the characteristic
histology of chronic CsA nephrotoxicity (Fig. 8). In the glomeruli,
none of the changes were statistically significant except for an
This report describes an animal model of chronic CsA nephro-
toxicity that mimics the functional and histopathological findings
observed in the human lesion of chronic-CsA induced injury.
Salt-depletion has been shown to accelerate CsA nephropathy
with the lesion developing by three to four weeks in the rat [12]
instead of three months or longer [30]. In this model, we found
that the histologic changes were accompanied by physiologic
changes namely increased creatinine, decreased creatinine clear-
ance, increased tubular enzymuria, and a loss of medullary
concentrating ability. While enzymuria stabilizes, the other phys-
iologic markers of CsA toxicity progress with continued treat-
ment.
The matrix expansion observed in this model was most marked
in the interstitial and vascular compartments of the kidney. This is
in accordance with the characteristic histology of chronic CsA
nephropathy that is interstitial fibrosis and arteriolopathy [5].
Although present in the cortex, the observed changes were mostly
in the medulla and were manifested by a dramatic increase in the
presence of TGF-pl, PAl-i and matrix proteins. These changes
were associated with a decrease in medullary concentrating
ability. In accordance with our observation, recent data have
shown that the early changes of CsA nephropathy are first seen in
the medullary compartment of the kidney [31, 32].
The common belief is that the chronic form of CsA injury is a
consequence of CsA-induced renal vasoconstriction. According to
this notion, the arteriolar vasospasm with resultant impairment in
renal blood flow leads to tubulointerstitial fibrosis. Data to
support the role of ischemia as a primary stimulus for tubuloin-
terstitial fibrogenesis have been offered [33]. However, more
recent studies have suggested that there can be a dissociation
between the functional and histological injuries induced by CsA
[13]. CsA withdrawal led to improved GFR but the degree of
tubular atrophy and interstitial fibrosis actually progressed [13]. In
our model, while acute tubular enzymuria stabilized, the associ-
ated histologic changes continued to progress during the fol-
low-up period and were dominated by renal fibrosis. Our findings
also indicate that the observed fibrosis was associated with an
increased deposition of the three major components of the ECM:
proteoglycans, glycoproteins, and collagens.
Certain matrix components have been shown to be up-regu-
lated with the administration of CsA. In cell cultures treated with
CsA, collagen type I and IV mRNAs were elevated in murine
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A B C
D E F
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Fig. 7. Immunofluorescence micrographs of CsA and VH-treated rat kidneys. Kidney sections from CsA treated rats for seven days (A, D, and G), for 28
days (B, E, and H) and VH controls (C, F, and 1) were stained with an antibody to tenascin (A, B, and C), fibronectin EDA+ (D, E, and F) and decorin
(G, H, and I). The photographs were taken under identical conditions with equal exposures of 60 seconds (magnification x250).
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Fig. 9. Quantitation of mRNA expression of TGF-f31, PAl-i and matrix
proteins in cortex versus medulla in CsA -treated rat kidneys. Total RNA was
isolated from whole cortex () and medulla (E) at days 7 (A) and 28 (B),
and was hybridized whh cDNA probes to TGF-pl, PAl-i, biglycan,
decorin, and type I collagen. Abbreviations are: biglycan (BO), decorin
(DEC), and type I collagen (COL I). *P < 0.001 compared to cortex.
Tenascin Fibro-EDA+ Decorin
Fig. 8. Quantitation of deposition of extracellular matrix components in CsA
and control treated rat kidneys by immunofluorescence. (A) Glomerular
staining, (B) tubulointerstitial staining, and (C) vessels staining scores at
days 7 and 28. Symbols are: (•) CsA 7 days; (hI) VH 7 days; () CsA 28
days, () VH 28 days. Abbreviation Fibro-EDA+ is fibronectin EDA+.P < 0.005 and ** < 0.001 compared to VH control.
1150 Shihab et al: TGF-/31 in CsA nephropathy
tubular cells [31, while no change was observed in a variety of rat
and human renal cells [35]. On the other hand, collagen type III
synthesis was increased in human mesangial cells and renal
fibroblasts treated with CsA [351. In addition, procollagen sl (I)
mRNA was shown to be elevated in the renal cortex of CsA-
treated rats [361. CsA was also recently shown to enhance TGF-p
mRNA expression in normal human T cell culture [37]. Another
cytokine, platelet-derived growth factor (PDGF), was shown to be
present in the arteriolar walls of CsA-treated rats [38]. However,
while most of the experiments done were in vitro, no study has
looked at the components of the fibrotic lesion of chronic CsA
nephrotoxicity in vivo, and none has attempted to correlate the
renal fibrosis with any growth factor.
Transforming growth factor-n (TGF-13) has been implicated in
the fibrosis of a number of chronic diseases of the kidney and
other organs [14, 15]. In addition, it is known to induce its own
production [39] and its persistent expression following repeated
injuries can lead to a cycle of continued TGF-/3 production [14].
TGF-13 causes fibrosis by stimulating synthesis of individual ECM
components and simultaneously blocking ECM degradation [16—
19]. In this model, we have observed an elevated expression of
representative members of the proteoglycans, glycoproteins and
collagen families. Their expression correlated with a parallel and
significant increase in TGF-131. In addition, the protease inhibitor
PAl-i was up-regulated and its expression followed closely the
expression of TGF-pl and the ECM proteins studied. Since
TGF-f31 directly stimulates PAl-i expression [19], our data sug-
gest that the observed ECM accumulation in this model likely
involves the dual action of TGF-13 on ECM deposition and
degradation.
What causes the elevation of TGF-13 remains unclear. Since
CsA directly stimulates TGF-p in vitro, it has been proposed that
the immune suppressive activities and renal fibrosis due to CsA
are both mediated by TGF-13 [37, 40, 411 and may explain the
elevated expression of TGF-131 in our model. It is also possible
that renal ischemia produced by the vasoconstriction of CsA
elevates TGF-/3 [42]. Since the current model is produced by
salt-depletion, the renin-angiotensin system (RAS) is activated
[32]. Interestingly, there is evidence to suggest that activation of
the RAS up-regulates TGF-f3. The renal RAS is induced by CsA
and plays an important role not only in the regulation of glomer-
ular hemodynamics but also in glomerular growth and sclerosis
[431. Angiotensin (Ang) II and CsA have been separately shown
to stimulate fibrogenesis by mechanisms independent of their
vasoconstrictive action [33, 44]. Chronic infusion of Ang II in rats
produce considerable interstitial fibrosis [45]. Ang converting
enzyme inhibitors and Ang II receptor antagonists attenuate
interstitial fibrosis and progressive glomerulosclerosis in several
disease models and slow disease progression in several human
studies [46, 47]. Kagami et al have recently demonstrated a link
between Ang II and TGF-/3 by showing that Ang II stimulation of
ECM protein synthesis in rat glomerular mesangial cells is
mediated by both an increase in TGF-/3 synthesis and an increase
in the conversion from latent to active TGF-p [48]. In addition,
CsA administration in salt-depleted rats caused a significant
increase in juxtaglomerular (JG) apparatus renin, and blockage of
the RAS with a competitive Ang II receptor antagonist, losartan,
reduced the formation of interstitial fibrosis [49]. While the
peripheral renin activity is often normal or suppressed in CsA-
treated renal transplants, there is abundant evidence of JG cell
hyperplasia within the kidney in such individuals similar to other
one-clip, one-kidney models of hypertension [50].
In conclusion, by using a model of chronic CsA nephropathy
that mimics the human lesion, we have shown that matrix proteins
are increased, mostly in the medulla, and more specifically in the
interstitial and vascular compartments of the kidney. We have
linked the expression of TGF-/31 to matrix expansion and have
shown that both TGF-131 and PAl-I are increased. We propose
that TGF-/31 is a key fibrogenic cytokine involved in the develop-
ment of chronic CsA nephropathy by enhancing ECM deposition
and inhibiting its degradation. However, other factors may also be
involved in the fibrosis of chronic CsA nephrotoxicity. Whether
long-term immunosuppression with CsA inevitably leads to renal
fibrosis is unknown and has not been excluded by any properly
controlled clinical study.
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